Skip to content

G&A at other companies

LeMaitre Vascular logo
LeMaitre VascularLMAT
$12.05M+14.9%

Other financials

Income statement

See full
Revenue$317.0M-1.3%
Gross profit$183.4M+3.2%
Operating income$25.4M+59.3%
Net income$13.8M+129%
EPS (diluted)$0.45+137%

Balance sheet

See full
Cash & equivalents$35.0M-1.3%
Total debt$862.6M-3.6%
Total equity$1.0B+4.1%
Total assets$2.3B+0.8%

Cash flow

See full
Operating cash flow$13.5M-67.6%
CapEx$2.9M-23.5%
Free cash flow$10.6M-72.0%

Valuation

See full
Market cap$1.04B-35.6%
Enterprise value$1.87B-24.5%
P/E19×+5.4×
P/S0.8×-0.5×

Profitability

See full
Gross margin55.2%-1.0pp
Operating margin8.2%-5.6pp
Net margin4%-5.0pp
FCF margin9%-3.5pp

Returns & leverage

See full
Return on equity5.5%-7.5pp
Debt / equity0.8×-0.1×
Current ratio2.3×0.0×

Where this comes from

Reported directly by CONMED in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: CONMED’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about CONMED's g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CONMED's G&A?
CONMED (CNMD) reported G&A of $32.4M in Q1 2026.
How has CONMED's G&A changed year-over-year?
CONMED's G&A decreased by 0.8% year-over-year, from $32.66M to $32.4M.
What is the long-term trend for CONMED's G&A?
Over 3 years (2022 to 2025), CONMED's G&A has grown at a 11.1% compound annual growth rate (CAGR), from $96.11M to $131.97M.
What does G&A mean?
Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.